CLIMP-63 is a gentamicin-binding protein that is involved in drug-induced cytotoxicity by Karasawa, T et al.
CLIMP-63 is a gentamicin-binding protein that is
involved in drug-induced cytotoxicity
T Karasawa*
,1, Q Wang
1, LL David
2 and PS Steyger
1
Aminoglycoside-induced nephrotoxicity and ototoxicity is a major clinical problem. To understand how aminoglycosides,
including gentamicin, induce cytotoxicity in the kidney proximal tubule and the inner ear, we identiﬁed gentamicin-binding
proteins (GBPs) from mouse kidney cells by pulling down GBPs with gentamicin–agarose conjugates and mass spectrometric
analysis. Among several GBPs speciﬁc to kidney proximal tubule cells, cytoskeleton-linking membrane protein of 63kDa
(CLIMP-63) was the only proteinlocalized inthe endoplasmic reticulum,and was co-localized with gentamicin-Texas Red (GTTR)
conjugate after cells were treated with GTTR for 1h. In western blots, kidney proximal tubule cells and cochlear cells, but not
kidney distal tubule cells, exhibited a dithiothreitol (DTT)-resistant dimer band of CLIMP-63. Gentamicin treatment increased the
presence of DTT-resistant CLIMP-63 dimers in both kidney proximal (KPT11) and distal (KDT3) tubule cells. Transfection of wild-
typeandmutantCLIMP-63into293Tcellsshowedthatthegentamicin-dependentdimerizationrequiresCLIMP-63palmitoylation.
CLIMP-63 siRNA transfection enhanced cellular resistance to gentamicin-induced toxicity, which involves apoptosis, in KPT11
cells.Thus,thedimerizationofCLIMP-63islikelyanearlystepinaminoglycoside-inducedcytotoxicityinthekidneyandcochlea.
Gentamicin also enhanced the binding between CLIMP-63 and 14-3-3 proteins, and we also identiﬁed that 14-3-3 proteins are
involved in gentamicin-induced cytotoxicity, likely by binding to CLIMP-63.
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Aminoglycosides are among the most commonly used
antibiotics in clinical practice,
1 and are essential for treating
life-threatening tuberculosis and Gram-negative bacterial
infections, such as meningitis, pulmonary infections in cystic
ﬁbrosis patients, and bacterial sepsis in infants.
2–4 However,
aminoglycosides can induce severe acute nephrotoxic and
permanent ototoxic side effects. Following systemic adminis-
tration, aminoglycosides are taken up by, and are cytotoxic
to, kidney proximal tubule epithelial cells, the primary site of
nephrotoxicity. Renal toxicity is largely reversible because of
the regenerative tubular epithelial cell proliferation.
5 Amino-
glycoside-induced ototoxicity, on the other hand, is mostly
permanent because these drugs primarily induce cytotoxicity
in cochlear sensory hair cells, which cannot spontaneously
regenerate in mammals following hair cell death.
6
Aminoglycosides enter eukaryotic cells by endocytosis and
are trafﬁcked to lysosomes, the Golgi complex and endo-
plasmic reticulum (ER) before being released into the
cytosol.
7–9 Aminoglycosides also permeate non-selective
cation channel directly into the cytoplasm.
10–12 In the cell,
aminoglycosides can induce cytotoxicity that results in both
apoptoticandnon-apoptoticcelldeathbyactivatingcaspase-3,
caspase-9, c-jun N-terminal kinases, calpains and cathespin
D, or generating toxic levels of reactive oxygen species.
13–17
How aminoglycosides induce these cell death mechanisms
remains unclear.
In this study, we identiﬁed gentamicin-binding proteins
(GBPs) from proximal tubule cells that may contribute to
drug susceptibility in these cells. Of these proteins, only the
cytoskeleton-linking membrane protein of 63kDa (CLIMP-63)
is localized in the ER membrane, and colocalized with
gentamicin-Texas Red (GTTR). CLIMP-63, also known as
CKAP4, is a type II transmembrane protein with a short
cytosolic domain and a long lumenal domain. The physiolo-
gical functions of CLIMP-63 have not been well documented,
but it is thought to be an anchoring protein connecting the ER
to the cytoskeleton.
18 The cytosolic domain of CLIMP-63
anchors the ER network to the microtubular cytoskeleton, and
the lumenal domain of CLIMP-63 is required for its oligomer-
izationandimmobilizationintheERmembrane.
18,19 Weshow
that gentamicin binds to the lumenal domain and induces
dimerization of CLIMP-63, that is dependent on palmitoyla-
tion. We also show that CLIMP-63 contributes to gentamicin-
induced apoptosis in proximal tubule cells, likely through
dimerization of CLIMP-63. Finally, we identiﬁed 14-3-3
proteins as CLIMP-63-binding proteins, and that gentamicin
enhances 14-3-3b binding to CLIMP-63 through 14-3-3y,
having a major role in gentamicin-induced cytotoxicity.
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To identify GBPs, we used mouse kidney cell lines as
described previously.
12 On the basis of morphological
differences, TRPV4 expression as a distal tubule marker,
and susceptibility to gentamicin treatment, cell lines of
proximal and distal tubule origins were identiﬁed.
12,20 The
susceptibility of a proximal tubule cell line, KPT11, to
gentamicin-induced toxicity was compared with KDT3, a
distal tubule cell line. After 3 days of gentamicin treatment,
KPT11 showed signiﬁcantly lower cell viability compared with
KDT3 (Figure 1a). Caspase-3 activity was signiﬁcantly higher
in KPT11 compared with KDT3, after 2 days of gentamicin
treatment (Figure 1b). These data conﬁrmed that the proximal
tubule cell line KPT11 is more susceptible to gentamicin
treatment compared with the distal tubule cell line KDT3, and
that cytotoxicity involves apoptotic mechanisms.
Identiﬁcation of GBPs. GBPs were pulled down from total
cell lysates of KPT11 and KDT3 by using gentamicin–
agarose conjugates, and resolved by SDS gel electrophor-
esis. Coomassie blue staining revealed that most of the GBP
bands were similar in density between these two cell lines
(Figure 1c). However, several GBP bands reproducibly had
greater density in KPT11 cells compared with KDT3 cells
(at least three times out of several electrophoresis runs;
Figure 1c). These KPT11-speciﬁc GBP bands were excised
and analyzed by mass spectrometry. Proteins identiﬁed with
the highest numbers of unique spectra for each band by
mass spectrometric analysis were considered valid GBPs
(Supplementary Table S1). These were proteins generally
associated with the cytoskeleton (myosin IIA, caldesmon,
actin, a-tropomyosin), including CLIMP-63 that anchors the
ER to the cytoskeleton. Western blotting data conﬁrmed that
each of these proteins was pulled down at higher levels in
KPT11 than KDT3 cells except for a-tropomyosin (Figure 1d).
It is possible that tropomyosin bands in the western blot
showed multiple tropomyosin isoforms and did not reﬂect the
levels of a-tropomyosin. Because of the sequence homology,
mass spectrometric analysis could not speciﬁcally distinguish
between b- and g-actin isoforms.
CLIMP-63 co-localizes with GTTR in the cell. KPT11
cells were treated with 5mg/ml GTTR in growth medium
for 1h. Lysosomal ﬂuorescence was quenched to detect
GTTR in organelles with low levels of uptake.
8,9 CLIMP-63
immunoﬂuorescence revealed a high degree of overlapping
Figure 1 Gentamicin-bindingproteinidentiﬁcation.(a)ProximaltubuleKPT11cellsanddistaltubuleKDT3cellswerecomparedforcellviabilityaftergentamicintreatment
for 3 days by MTT assay. KPT11 cells had signiﬁcantly lower viability compared with KDT3 cells following 10mM gentamicin treatment (**Po0.01). (b) Gentamicin (10mM)
induced signiﬁcantly more caspase-3 activity in KPT11 cells compared with KDT3 cells (*Po0.05). Data in a and b are shown as mean±S.D. of three independent
experiments. (c) GBPs were pulled down from total cell lysates of KPT11 and KDT3 cells. SDS-polyacrylamide gel electrophoresis followed by Coomassie blue staining
revealed several GBP bands speciﬁc to KPT11 cells (representative gel from three experiments). Mass spectrometric analysis of peptides from excised gel bands identiﬁed
these GBPs with the highest numbers of unique peptides. (d) Western blotting on the pull-down samples conﬁrmed the GBPs identiﬁed by mass spectrometry
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Cell Death and Diseaselocalization with GTTR in the cytoplasm (Figures 2a–c).
Myosin IIA and caldesmon had distinctively different
immunolocalization patterns from CLIMP-63 and little
co-localization with GTTR (Figures 2d–f, data not shown).
As previous studies on CLIMP-63 were primarily conducted
on monkey kidney COS-7 cells,
18,19 we also examined
GTTR and CLIMP-63 localization in COS-7 cells, and
observed signiﬁcant co-localization of GTTR with CLIMP-63
(Figures 2g–l). Although gentamicin may bind to myosin IIA
and caldesmon, their weak colocalization with GTTR
suggests that their interactions may not have signiﬁcant
roles in inducing toxicity. Therefore, we sought to determine
whether CLIMP-63 has a role in gentamicin-induced toxicity
in the cell.
Different oligomerization states of CLIMP-63 in kidney
tubule cells. Although suggested before,
21 ubiquitous
expression of CLIMP-63 has not been conﬁrmed. CLIMP-63
mRNA expression was detected in all mouse tissues tested
by RT-PCR, and was lower in the kidney compared with
most other tissues (Figure 3a). CLIMP-63 expression was
higher in proximal tubule cell lines (KPT11 and KPT2
12)
compared with distal tubule cell lines (KDT3 and MDCT;
22
Figure 3b). This was conﬁrmed by western blotting
(Figure 3c). TRPV4 expression is a marker for distal tubule
cells
20 (Figure 3c). There was no signiﬁcant difference
between proximal and distal tubule cells in expression
levels of calreticulin (CRT), a previously identiﬁed GBP.
23
Remarkably, proximal tubule cells also exhibited a second
Figure 2 CLIMP-63 co-localizes with GTTR. Cells were treated with GTTR for 1h before immunolabeling for GBPs. CLIMP-63 and GTTR had highly overlapping
localization (a–c), whereas myosin IIA and GTTR showed no signiﬁcant co-localization (d–f) in KPT11 cells. GTTR in COS-7 cells was not evenly distributed in the cytoplasm
andwas highlyco-localizedwithCLIMP-63,as indicatedbyarrows(g–l).Scalebarina alsoappliesforb–i (20mm).Imagesj–lweremagniﬁedfromlower-rightcornerofg–i,
and scale bar in j also applies for k and l
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Cell Death and Diseaseband that corresponds to the dimeric form of CLIMP-63
(Figure 3c). CLIMP-63 forms oligomers that can be detected
in non-reducing conditions without dithiothreitol (DTT).
24
In non-reducing conditions ( DTT), bands were observed
B126 and 252kDa in all samples tested (Figure 3c),
likely dimers and tetramers of CLIMP-63. The high
molecular mass bands in reducing conditions (þDTT) were
at the same position as in non-reducing conditions,
suggesting that these were also dimers. Resistance of
dimers to reducing conditions suggests that these are likely
formed by non-disulﬁde bonding. As mouse ﬁbroblast 3T3
cells also showed similar levels of CLIMP-63 monomer
expression as KPT11 cells, but with negligible levels of
dimers in western blots, these DTT-resistant dimers are not
likely due to high levels of CLIMP-63 expression
(Supplementary Figure S1A and B).
The lumenal domain of CLIMP-63 forms a coiled-coil
structure that is required for oligomerization.
19 As only
proximal tubule cells showed the DTT-resistant dimers in
western blots, CLIMP-63 oligomerization states in kidney
proximal and distal tubule cells are likely different. To
determine whether CLIMP-63 interacts with gentamicin at
the N-terminal cytosolic domain or the C-terminal lumenal
domain, GST fusion proteins of CLIMP-63 domains were
generated for gentamicin–agarose pull-down assays. Genta-
micin–agarose pulled down the lumenal domain of CLIMP-63
in signiﬁcantly high amounts, as revealed by Coomassie blue
staining (Figure 3d). The cytosolic domain was only weakly
pulled down by gentamicin–agarose, but this was likely
non-speciﬁc binding, as GST alone was also pulled down at
a similar level by agarose without gentamicin. These data
suggest that CLIMP-63 and gentamicin interact with each
other within the ER lumen.
A cochlear cell line expresses CLIMP-63 with a
modiﬁcation similar to proximal tubule cells. In the
kidney, proximal tubule cells express greater levels of
monomeric CLIMP-63 and DTT-resistant dimers than distal
tubule cells. The inner ear is another primary site for
aminoglycoside toxicity. We analyzed cochlear cell lines for
the presence of CLIMP-63 dimers. HEI-OC1 (organ of Corti
cell line) and SV-k1 (stria vascularis cell line) are cochlear
cell lines of similar genetic background from transgenic
mice,
25,26 with cells transformed by a temperature-sensitive
mutant of large T-antigen. These cells grow rapidly at
331C (permissive), but adopt a more differentiated state at
391C (non-permissive). Interestingly, a high level of the
non-reducible CLIMP-63 dimers appeared in HEI-OC1 cells
at the non-permissive condition (391C) but not at the
permissive condition (331C; Figure 4a). RT-PCR showed
that there was no signiﬁcant difference in expression of
CLIMP-63 at the transcription level in HEI-OC1 cells grown at
non-permissive conditions, although b-actin expression was
reduced (Figure 4b). As the non-permissive condition did not
enhance dimer formation in SV-k1 cells, dimerization is likely
organ of Corti speciﬁc, and could also occur in vivo.
Figure3 DifferentexpressionlevelsofCLIMP-63,oligomerizationofCLIMP-63,andgentamicinbindingtotheCLIMP-63lumenaldomain.(a)RT-PCRofspeciﬁedmouse
tissues revealed varying CLIMP-63 expression levels. (b) RT-PCR of mouse kidney cell lines show higher levels of CLIMP-63 mRNA expression in proximal tubule cells
compared with distal tubule cells. (c, left panel) Proximal, but not distal, tubule cells express DTT-resistant dimers of CLIMP-63, revealed by western blotting. (c, right panel)
WithoutDTT, allsamples displayedbands that correspond to dimersand tetramers.(d)The GSTfusionsof the cytosolicdomain(p63-Cyto) and lumenaldomain(p63-lumen)
had approximate molecular masses of 42 and 75kDa, respectively, as revealed by Coomassie blue staining (shown as ‘input’). p63-lumen was efﬁciently pulled down,
whereas negligible GST or weak p63-Cyto proteins were pulled down by gentamicin–agarose (GT). There were no GST fusions pulled down by agarose without gentamicin
conjugation (no GT), although a weak GST band was detected
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Cell Death and DiseaseGentamicin induces DTT-resistant dimerization of
CLIMP-63. To determine whether gentamicin affects
CLIMP-63, we treated KPT11 and KDT3 cells with genta-
micin. After 3 days of gentamicin treatment, KPT11 cells
showed increased levels of dimers, and possibly monomers
of CLIMP-63, by western blotting (Figure 4c). Importantly,
KDT3 cells that normally do not exhibit the non-reducible
dimers also contained a dimer band after gentamicin
treatment (Figure 4c), suggesting that gentamicin induces
DTT-resistant CLIMP-63 dimers. This also implicates that
CLIMP-63 dimerization is associated with gentamicin-
induced cytotoxicity.
CLIMP-63 palmitoylation is required for the gentamicin-
induced DTT-resistant dimerization. A post-translational
modiﬁcation, palmitoylation, has been associated with
CLIMP-63 subcellular localization.
27,28 To test whether
palmitoylation and DTT-resistant dimerization of CLIMP-63
are related, we transfected wild-type and palmitoylation-
incompetent mutants of CLIMP-63 (C100S and C100A)
into human embryonic kidney 293T cells, and analyzed the
state of CLIMP-63 by western blotting. Overexpression of
wild-type CLIMP-63 resulted in a band corresponding to the
dimer species, but the mutants did not show signiﬁcant levels
of dimers (Figure 4d). Interestingly, CLIMP-63-transfected
293T cells treated with gentamicin for 3 days increased the
amount of the DTT-resistant dimers in the wild-type transfected
cells, but not mutant transfected cells. There was no signiﬁcant
difference in subcellular localization between the transfected
wild-type CLIMP-63 or either mutant in COS-7 cells (Figure 4e).
Although the monoclonal antibody also detected endogenous
CLIMP-63 (Figure 2j), the localization patterns of endogenous
and transfected CLIMP-63 were distinctively different (Figure 2j
and Figure 4e).
18 Therefore, gentamicin-induced dimerization
of CLIMP-63 requires palmitoylation, and the inability of mutant
to form the dimer is not because of the changes in subcellular
localization.
CLIMP-63 contributes to gentamicin-induced toxicity in
kidney proximal tubule cells. To determine whether
CLIMP-63 in proximal tubule cells contributes to gentamicin
cytotoxicity, two sets of siRNA for CLIMP-63 and scrambled
control were designed and generated. Transfection of
CLIMP-63 siRNA reduced protein expression levels of the
DTT-resistant dimer in KPT11 cells, although there was
no apparent reduction in the monomer form (Figure 5a).
RT-PCR showed that siRNA effectively reduced CLIMP-63
transcripts (Figure 5b). CLIMP-63 siRNA transfection into
KPT11 resulted in B5–10% reduction in cell number, after 3
days of transfection, compared with cells transfected with
Figure 4 CLIMP-63 in a cochlear organ of Corti cell line forms the DTT-resistant dimers, and gentamicin induces the dimerization of the CLIMP-63 that is dependent on
palmitoylation.(a)Inthenon-permissivecondition(391C),theorganofCortiHEI-OC1celllineexpressedtheDTT-resistantdimerformofCLIMP-63inwesternblots.However,
there was minimal dimer induction in stria vascularis SV-k1 cells in either condition. (b) CLIMP-63 gene expression levels were not altered in HEI-OC1 cells in the
non-permissive condition, conﬁrmed by RT-PCR. (c) After gentamicin treatment at 5mM for 3 days, both KPT11 and KDT3 expressed higher levels of the DTT-resistant
dimers, and higher monomer levels in KPT11 cells in western blots. (d) Cells (293T) transfected with the wild-type CLIMP-63 (p63WT) formed the DTT-resistant dimers, but
those with palmitoylation-incompetent mutants C100S and C100A (p63CS and p63CA) showed reduced amounts of the dimers compared with the wild type. Gentamicin
treatment increased the dimer level only in cells transfected with the wild-type CLIMP-63. (e) COS-7 transfected with the CLIMP-63 wild type (p63WT) or C100A mutant
(p63CA) showed microtubule associated expression. The C100S mutant also showed similar expression pattern (data not shown)
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Cell Death and Diseasecontrol siRNA (data not shown). However, after 3 days of
gentamicin treatment, CLIMP-63 siRNA-transfected KPT11
cells had higher cell viability compared with control cells
(Figure 5c). To measure caspase-3 activity, proteins were
extracted from siRNA-transfected KPT11 cells after 24h of
gentamicin treatment. Strikingly, CLIMP-63 siRNA trans-
fection suppressed gentamicin-dependent caspase-3 activity
completely, whereas 10mM gentamicin increased caspase-3
activity twofold in control siRNA-transfected cells (Figure 5d).
Gentamicin-induced caspase-3 activity continued to increase
after 12 and 24h (Supplementary Figure S1C). Conﬁrmation
that caspase-3 activation was due to apoptosis was provided
by terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) assays. After 24h of gentamicin
treatment, B10% of control siRNA-transfected KPT11 cells
were positive for TUNEL labeling, whereas most CLIMP-63
siRNA-transfected cells showed no labeling in the nuclei
(o1% of the cell population; Figure 5e).
Experiments with KDT3 cells were also performed using
CLIMP-63 siRNA transfection and gentamicin treatment, to
compare the differences between kidney proximal and distal
tubule cells. The efﬁcacy of siRNA transfection was conﬁrmed
by RT-PCR (Supplementary Figure S1D). CLIMP-63 siRNA-
transfected cells did not show signiﬁcantly different cell
viability or caspase-3 activity compared with control siRNA-
transfected cells after gentamicin treatment, although there
appeared to be minor effects in reducing the toxicity
(Supplementary Figure S1E, F). These data also suggest
that CLIMP-63-dependent gentamicin cytotoxicity requires
the DTT-resistant dimer of the protein.
Figure 5 Reducing CLIMP-63 dimer expression by siRNA transfection enhances cellular resistance to gentamicin-induced toxicity. (a) Two sets of siRNA for CLIMP-63
and scrambled control were transfected into KPT11 cells. Although the monomer form of CLIMP-63 (p63 monomer) did not show any apparent reduction, the DTT-resistant
dimer form (p63 dimer) was reduced by siRNA for CLIMP-63 (p63 siRNA no. 1 and no. 2) as shown by western blotting. (b) CLIMP-63 gene knockdown by siRNA was
conﬁrmed by RT-PCR. (c) After 3 days of gentamicin treatment, cell viability was higher in CLIMP-63 siRNA-transfected cells compared with control, as determined by MTT
assay (*Po0.05 between control and p63 siRNA no. 1, **Po0.01 between control and p63 siRNA no. 2). (d) Caspase-3 activity was suppressed in cells transfected by
CLIMP-63siRNA after 24h of gentamicin treatment (*Po0.05 between control and p63 siRNA no. 1, **Po0.01 between control and p63 siRNA no. 2). Data in (c and d) are
shown as mean±S.D. of three independent experiments. (e) DNA strand breaks were detected by TUNEL reaction in control siRNA-transfected KPT11 after 24h of
gentamicin treatment, but not in CLIMP-63 siRNA-transfected cells. Phalloidin labeled the ﬁlamentous actin cytoskeleton, allowing visualization of cell morphology
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Cell Death and DiseaseCLIMP-63 binds to 14-3-3 proteins and gentamicin
enhances their interaction. CLIMP-63 may induce
gentamicin cytotoxicity through binding to other proteins.
To identify such proteins, FLAG-tagged CLIMP-63 (FLAG-
p63) was transfected into 293T cells, and cells were treated
with gentamicin for 24h. FLAG-p63 was immunoprecipitated
with anti-FLAG antibody, and the samples were analyzed by
SDS-gel electrophoresis followed by silver staining. A band
speciﬁc to cells treated with gentamicin was detected in the
28kDa region (Figure 6a). Mass spectrometric analysis of
this band identiﬁed a number of proteins, and those that ﬁt
the molecular mass of B28kDa were 14-3-3 proteins. On the
basis of results from two separate experiments, these were
identiﬁed as 14-3-3y, 14-3-3b, 14-3-3z, and 14-3-3e.A s
14-3-3y and b were the predominant 14-3-3 proteins to be
identiﬁed, we explored their interactions with CLIMP-63 and
their possible roles in gentamicin-induced apoptosis.
To conﬁrm the interactions between CLIMP-63 and 14-3-3
proteins, 293T cells were co-transfected with FLAG-p63
and Myc-tagged 14-3-3b and y (Myc-14-3-3b and y). FLAG
immunoprecipitation was performed on cell lysate from
transfected cells, and samples were analyzed by western
blotting. Unexpectedly, only Myc-14-3-3y was co-immuno-
precipitatedwith FLAG-p63(Figure 6b).CLIMP-63interaction
with 14-3-3y was further conﬁrmed by GST fusion pull-down
assay using GST fusion proteins of CLIMP-63 domains. GST
Figure 6 CLIMP-63 binds to 14-3-3y, which in turn binds to 14-3-3b.( a) Immunoprecipitation was conducted on cell lysate from FLAG-tagged CLIMP-63 (FLAG-p63)-
transfected 293T cells, using anti-FLAG antibody. SDS-gel electrophoresis followed by silver staining revealed a band speciﬁc to cells treated with 5mM gentamicin for 24h
(þGT), which was not present in no gentamicin control ( GT), as indicated by an arrow. Mass spectrometry on the band identiﬁed 14–3–3b and y. FLAG-p63 band is
indicatedbyanarrowhead.Thebandwaswhitebecauseofthesilverstainingsaturationeffect.(b)293Tcellswereco-transfectedwithFLAG-p63andMyc-tagged14–3–3bor
y (Myc-14–3–3b or y), and immunoprecipitation using anti-FLAGantibody was performed after 24h of incubation. FLAG-p63 was co-immunoprecipitated with Myc-14–3–3y,
butnotb.(c)GSTfusionpull-downassaywasperformedoncelllysatefromMyc-14-3-3y-transfected293Tcells.CoomassiebluestainingofGSTfusionsfollowedbySDS-gel
electrophoresisconﬁrmedthatcomparablelevelsofGSTfusionswereused(leftpanel).Westernblottingonthepull-downsamplesshowedthatMyc-14-3-3ybindsonlytothe
cytosolicdomainofCLIMP-63(p63-Cyto),andnottoGSTorthelumenaldomain(p63-lumen).(d)FLAG-taggedGFPor14-3-(FLAG-GFPor14-3-3y)wasco-transfectedwith
Myc-14-3-3b. Immunoprecipitation using anti-FLAG antibody also pulled down Myc-14-3-3b, suggesting that 14-3-3y and b binds with each other, probably forming a dimer.
(e)COS-7 cells wereco-transfectedwith CLIMP-63and Myc-14–3–3y or b. In theabsenceof exogenousCLIMP-63expression,Myc-14-3-3y was localized inthe cytoplasm,
andco-localizationwithendogenousCLIMP-63was notveryclear (upperpanels).CLIMP-63overexpressionalteredlocalizationsofnotonlyCLIMP-63butalso Myc-14-3-3y,
more distributed along peripheral sites of cells (middle panels). There was also signiﬁcant co-localization between CLIMP-63 and Myc-14–3–3y, as indicated by arrows.
Myc-14-3-3b did not show clear co-localization with overexpressed CLIMP-63, but still altered localization, possibly through endogenous 14-3-3y protein (lower panels)
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Cell Death and Diseasefusion protein-bound glutathione was mixed with cell lysate
from 293T cells transfected with Myc-14-3-3y, and binding
proteins pulled down. SDS-gel electrophoresis followed by
westernblottingshowedthatthecytosolicdomainofCLIMP-63
binds to Myc-14-3-3y (Figure 6c).
As 14-3-3b was identiﬁed as CLIMP-63-binding protein in
mass spectrometry but not in co-immunoprecipitation experi-
ments, we explored the possibility that 14-3-3b interacts with
CLIMP-63 through 14-3-3y by forming a heterodimer between
14-3-3b and y. Myc-14-3-3b was co-transfected with FLAG-
tagged GFP or 14-3-3y (FLAG-GFP or FLAG-14-3-3y) into
293T cells, and immunoprecipitation with anti-FLAG anti-
body and western blotting showed that FLAG-14-3-3y, but not
FLAG-GFP, co-immunoprecipitated Myc-14-3-3b (Figure 6d).
A reciprocal experiment using FLAG-14-3-3b and Myc-14-3-3y
also conﬁrmed that 14-3-3b interacts with 14-3-3y (data
not shown).
To determine whether CLIMP-63 interacts with 14-3-3
proteins in the cell, CLIMP-63 was co-transfected with Myc-
14-3-3y or b into COS-7 cells, and immunoﬂuorescence was
performed after 24h. The ER localization of endogenous
CLIMP-63 was overlapped with Myc-14-3-3y and b, but their
co-localization was not very clear (Figure 6e, upper panels,
and data not shown). CLIMP-63 transfection re-organized the
localization of the protein as shown before (Figure 4e),
and most importantly, Myc-14-3-3y localization was altered
and there was signiﬁcant co-localization with CLIMP-63
(Figure 6e, middle panels). Myc-14-3-3b localization was
also changed by CLIMP-63 transfection, although there was
no clear indication that they were co-localized (Figure 6e,
lower panels). It is possible that exogenous CLIMP-63
changed Myc-14-3-3b localization through endogenous
14-3-3y or other 14-3-3 proteins that bind to CLIMP-63.
Protein 14-3-3b contributes to gentamicin-induced
cytotoxicity. Having established that 14-3-3 proteins are
CLIMP-63-binding proteins, we investigated the possibility
that these proteins have a role in gentamicin-induced
apoptotic mechanisms. We designed and obtained siRNA
duplexes for 14-3-3b and y, and transfection into KPT11 cells
conﬁrmed that these siRNA efﬁciently knocked down protein
expression (Figure 7a). Without gentamicin treatment, siRNA
for each 14-3-3 lowered cell viability, approximately half of
those transfected with control siRNA (Figure 7b). This is
consistent with previous studies that 14-3-3 proteins are
crucial for cellular growth.
29 Gentamicin treatment for 3 days
further reduced cell viability of 14-3-3 siRNA-transfected
cells, as well as control cells. However, normalization of
cell viability with respect to gentamicin treatment revealed
that 14-3-3b siRNA-transfected cells showed signiﬁcantly
more viability compared with other siRNA-transfected
cells (Figure 7c). This was not because of the low basal
viability by 14-3-3 siRNA, because the raw cell viability assay
data at 10mM gentamicin showed that signiﬁcantly more
14-3-3b siRNA-transfected cells were viable than control
cells (A540¼0.47±0.07 versus 0.35±0.06; Po0.05).
Strikingly, there was no increase in caspase-3 activity in
14-3-3b siRNA-transfected cells after 24h of gentamicin
treatment (Figure 7d). Therefore, we concluded that 14-3-3b
has a role in gentamicin-induced apoptosis.
Figure 7 14-3-3b protein is required for CLIMP-63-dependent gentamicin-induced cytotoxicity. (a) KPT11 cells were transfected with siRNA for 14-3-3b and y, and cells
werelysedafter3days.WesternblottingshowedthatsiRNAcouldknockdownproteinexpressionathighefﬁciencies.(b)InMTTassay,14-3-3siRNA-transfectedKPT11cells
exhibited lower cell viability compared with control siRNA-transfected cells (*Po0.05, **Po0.01 against respective control). (c) Gentamicin treatment decreased viability of
cells transfected with all siRNA after 3 days, but those transfected with 14-3-3b siRNA were resistant to gentamicin (*Po0.05). Although 14-3-3b siRNA-transfected cells
showed lower viability compared with control, the MTT assay raw data at 10mM gentamicin showed that more cells were viable than control cells (A540¼0.47±0.07 versus
0.35±0.06). (d) Caspase-3 activity did not increase in cells transfected with 14-3-3b siRNA after 24h of gentamicin treatment, as opposed to cells with control siRNA,
which showed42.5-fold increase at 10mM. Without gentamicin treatment,there was no signiﬁcant difference in caspase-3 activity between 14-3-3b siRNA and control cells
(14-3-3b siRNA: A405¼0.09±0.05, control: A405¼0.12±0.07). Data in (b, c, and d) are shown as mean±S.D. of three independent experiments
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Although several mechanisms for aminoglycoside-induced
toxicity have been described, none has been fully elucidated.
Importantly, most studies concerning aminoglycoside toxi-
city address the mechanisms but overlook tissue speciﬁcity.
For example, aminoglycosides binding to ribosomal RNA
could induce toxicity, but why do the kidney and cochlea have
greater susceptibility to the drug? We hypothesized that
differences in protein expression may be responsible for the
susceptibility of particular cell types in the kidney and cochlea,
and that aminoglycosides must interact with intracellular
proteins to trigger cell death mechanisms, particularly
apoptosis. To identify proteins that bind to aminoglycosides,
we used a gentamicin–agarose conjugation technique
similar to those reported previously,
23,30 with an advantage
of including a spacer between gentamicin and agarose to
reduce steric hindrance of binding sites.
Kidney proximal tubule cells are more susceptible to
gentamicin compared with kidney distal tubule cells. Pre-
viously identiﬁed GBPs, CRT, and HSP73, are ubiquitously
expressed in kidney cells, and thus unlikely to be the GBPs
responsible for gentamicin susceptibility in proximal tubule
cells.
23,30,31 The GBP pull-down assay revealed greater
expressionofseveralGBPsinproximaltubulecellscompared
with distal tubule cells. Mass spectrometric analysis identiﬁed
these proteins as mostly cytoskeleton-associated proteins.
To identify GBPs that may have physiological relevance, we
determined the intracellular localization of GBPs and ﬂuor-
escent dye-tagged gentamicin (GTTR), previously used to
identify cellular mechanisms of gentamicin uptake.
12,32 As
well documented by others,
9 GTTR was localized mostly in
cytoplasm, with some punctate labeling, likely in endosomes
and in the ER. Subcellular localization analysis of these GBPs
determined that only CLIMP-63 had signiﬁcant overlapping
localization with GTTR.
CLIMP-63 has a leucine zipper motif in its lumenal domain,
28
the gentamicin-binding site identiﬁed in this study, and it is
predicted that CLIMP-63 forms a dimer similar to other proteins
with leucine zippers. Although examining the western blots of
CLIMP-63 derived from proximal and distal tubule-derived cells,
we found signiﬁcant amounts of disulﬁde-linked dimers.
Furthermore, CLIMP-63 from proximal cells was unique as
there were also non-disulﬁde-linked dimers. Similar non-
disulﬁde-linked CLIMP-63 dimers were also found in a cell line
derived from the cochlear organ of Corti, a region also
susceptible to gentamicin toxicity. Interestingly, gentamicin
treatment increased the formation of these non-disulﬁde-linked
dimers. How these non-disulﬁde-linked dimers have a role in
gentamicin-induced cytotoxicity is unclear, but our data suggest
thatitlikelychangesCLIMP-63structureatthecytosolicdomain,
because a mutation of the palmitoylation site in the cytosolic
domain inhibited the dimerization induced by gentamicin.
As a ﬁrst step to elucidate gentamicin-induced cytotoxicity
mechanisms of CLIMP-63, we used FLAG immunoprecipita-
tion and identiﬁed 14-3-3 proteins as CLIMP-63 binding
proteins. Co-immunoprecipitation and in vitro binding assays
showed that 14-3-3ybut not 14-3-3bdirectly binds to CLIMP-63,
and the binding site on CLIMP-63 is the cytosolic domain.
We also demonstrated that 14-3-3b and y bind with each
other, likely forming a heterodimer.
33,34 As 14-3-3b protein
was identiﬁed as a CLIMP-63-binding protein by mass
spectrometry, it is likely that it binds to CLIMP-63 through
14-3-3yoranother14-3-3familyprotein.Interactionsbetween
CLIMP-63 and 14-3-3 proteins were also conﬁrmed by
immunoﬂuorescence.
Finally, to test whether CLIMP-63 expression itself affects
drug susceptibility of the cells, we used siRNA transfection
instead of protein overexpression, because for most proteins,
overexpression itself can be highly toxic to cells. Conveni-
ently, the siRNA much reduced the dimer levels of CLIMP-63
in KPT11 cells, but not monomer levels. Thus, CLIMP-63
siRNA-transfected KPT11 cells could be considered similar to
distal tubule cells. Cell viability measurement, caspase-3
assays and TUNEL staining revealed that CLIMP-63 siRNA-
transfected KPT11 showed higher resistance to gentamicin
treatment comparedwithcontrolsiRNA-transfected cells.The
lack of caspase-3 activity observed in CLIMP-63 siRNA-
transfected KPT11 cells after treatment with gentamicin is
particularly signiﬁcant because it suggests that gentamicin-
induced caspase-3 activation requires CLIMP-63 dimeriza-
tion. However, CLIMP-63 siRNA-transfected KPT11 cells are
likely to be susceptible to other cell death mechanisms
induced by gentamicin, such as necrosis and caspase-
3-independent apoptosis.
17
To determine whether 14-3-3 proteins have a role in
gentamicin-induced cytotoxicity, we also designed and
obtained siRNA for 14-3-3b and y. Without gentamicin
treatment, these siRNA reduced cellular growth by B50%, as
expected because of known 14-3-3 functions in the cell cycle.
However, normalization to reveal the effects of gentamicin
demonstrated that 14-3-3b protein signiﬁcantly contributes to
gentamicin-induced cytotoxicity, particularly with increased
caspase-3 activity that leads to apoptosis. Although it is not
clear why knockdown of 14-3-3y did not attenuate gentamicin-
induced cytotoxicity, it is possible that 14-3-3b is the primary
14-3-3proteinthathasamechanisticroleingentamicintoxicity,
and it can bind to CLIMP-63 indirectly through a 14-3-3 protein
otherthan14-3-3y,toinducethesignalingmechanism.14-3-3z
and e proteins are candidates because these were also
identiﬁed as CLIMP-63-binding proteins.
Although the physiological functions of CLIMP-63 in the cell
are not well characterized, especially compared with 14-3-3
proteins, previous studies report that CLIMP-63 functions in
cellularproliferationasCLIMP-63expressionisupregulatedbya
cyclin-dependent kinase inhibitor olomoucine.
35 DHHC2, a
palmitoyl acryltransferase that palmitoylates CLIMP-63, also
regulates cellular proliferationthroughantiproliferative factor and
CLIMP-63.
28 It is possible that gentamicin induces cell death by
interfering with cellular proliferation control through CLIMP-63
and 14-3-3 proteins. Future studies on CLIMP-63 and 14-3-3
proteins with gentamicin and other aminoglycosides could
provide more insight into drug-induced toxicity mechanisms.
Materials and Methods
Antibodies. Primary antibodies used in this study are: myosin IIA polyclonal
antibody (pAb; Covance, Princeton, NJ, USA), caldesmon monoclonal antibody (mAb;
C21, Sigma, St. Louis, MO, USA), CLIMP-63 pAb (a generous gift from Dr. Jack
Rohrer, Zurich University of Applied Sciences, Switzerland) and mAb (G1/296, Alexis
Biochemicals, San Diego, CA, USA), actin pAb (Sigma, cat. no. A2103), tropomyosin
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Cell Death and DiseasepAb (E-17, Santa Cruz Biotechnology, Santa Cruz, CA, USA), TRPV4 pAb
(a generous giftfromDr.StefanHeller,StanfordUniversity,Stanford, CA,USA), CRT
pAb (Afﬁnity BioReagents, Golden, CO, USA), GAPDH mAb (GAPDH-71.1, Sigma),
FLAGmAb(M2,Sigma),MycmAb(9E10,Sigma),14-3-3bmAb(60C10,SantaCruz
Biotechnology), and 14-3-3y mAb (3B9, Santa Cruz Biotechnology).
Cell culture. Mouse kidney primary cultures were generated as described
previously.
12 COS-7, 293T, MDCT,
22 and NIH-3T3 cells as well as the kidney cell
lines we generated (KPT11, KPT2,
12 KDT3) were maintained at 371C, 5% CO2.
HEI-OC1 and SV-k1 cells (generous gifts from Dr. Federico Kalinec, House Ear
Institute, Los Angeles, CA, USA) were maintained at 331C with 10% CO2 (for the
permissive condition), or 391C with 5% CO2 (for the non-permissive condition).
All cells were maintained in DMEM with 10% FBS.
Gentamicin–agarose pull-down assay. Cells were lysed in buffer
containing 150mM NaCl, 50mM Tris, pH 7.5, 5mM EDTA, 1% Triton X-100 with
protease inhibitors, and centrifuged (14000g, 10min) at 41C to remove cell debris.
Protein concentration was adjusted to 1mg/ml for all samples. For gentamicin–
agarose preparation, 100ml Afﬁ-Gel 10 (Bio-Rad, Hercules, CA, USA) was washed
with ice-cold water three times and resuspended in 1ml HEPES (pH 7.0), in which
20mg of gentamicin had been dissolved. The suspension was incubated at 41C
overnight. The residual reactive sites on the beads were blocked by 1M
ethanolamine (pH 8.0) for 1h, and the beads were washed with PBS three times
and stored at 41C until use. The gentamicin–agarose conjugate was incubated with
whole-cell extract of proximal or distal tubule cells (1.5ml) for 1h at 41C. The beads
with bound proteins were spun down by brief centrifugation, washed three times
withthesamelysisbufferat41C.Theproteinswerethenremovedfromgentamicin–
agarose in SDS sample buffer, boiled for 2min, and separated by protein gel
electrophoresis (8% gel) prior to Coomassie blue staining.
Mass spectrometry. Gentamicin-binding protein bands from KPT11 cells
were excised from Coomassie-stained gels, washed twice for 30min in 50mM
ammonium bicarbonate/50% (v/v) acetonitrile, reduced in 10mM DTT/100mM
ammonium bicarbonate, alkylated in 55mM iodoacetamide/100mM ammonium
bicarbonate, and dehydrated gels reswelled in digestion buffer containing 50mM
ammonium bicarbonate/5mM CaCl2/12.5ng/ml sequencing grade modiﬁed trypsin
(Promega, Madison, WI, USA). Following an overnight incubation at 371C,
extracted peptides were identiﬁed by collection of MS/MS data using either a LTQ
linear ion trap mass spectrometer (ThermoFisher, San Jose, CA, USA) or a Q-Star
XL hybrid quadrupole-TOF mass spectrometer (Applied Biosystems, Foster City,
CA, USA). Peptides analyzed using the LTQ were separated using an Agilent 1100
series capillary LC system (Agilent Technologies Inc., Santa Clara, CA, USA) and
0.5 250mm Zorbax SB-C18 column (Agilent Technologies), and peptides
analyzed by the Q-Star XL were separated using a nano LC system (Eksigent
Technologies, Dublin, CA, USA) and 75mm 10cm nanospray column ﬁlled with
Astrosil C18 packing (Stellar Phases Inc., Langhorne, PA, USA). Proteins were
identiﬁed by collection of data-dependent MS/MS spectra and matching of the
MS/MSspectratoamousesubsetoftheUniprot,version15.4database(containing
60784 entries), and specifying a static þ57 mass for cysteines, and a differential
mass of þ16 for methionines using the program Sequest (version 27, rev. 12,
Thermo Finnigan, San Jose, CA, USA). The database was also amended with an
equal number of decoy sequence-reversed entries to independently assess the
protein false discovery rate. Protein identiﬁcation was then validated using the
program Scaffold (version 2_04_00, Proteome Software Inc., Portland, OR, USA),
which uses a probabilistic model to estimate the peptide and protein false discovery
rate.
36,37 Minimum peptide and protein probabilities were set at 80 and 99%,
respectively, with a minimum of ﬁve unique peptide matches per protein. Using
these criteria, there were no matches to the decoy proteins with reversed
sequences. Cytoskeleton-associated protein 4 (B2RRB4, also known as
CLIMP-63) was identiﬁed by 24 unique peptides, tropomyosin 1a (Q564G1) by
27 unique peptides, caldesmon 1 (Q8VCQ8) by 36 unique peptides, actin by
8uniquepeptides,andmyosin-9(Q8VDD5,alsoknownasmyosinIIA)by20unique
peptides. Because of the sequence homology, the identiﬁed peptides from actin
matched equally well to b- and g-actins (P60710 and P63260). Thus, the speciﬁc
isoform(s) of actin were not distinguished. Similar methods and criteria were used
for identiﬁcation of 14-3-3 proteins as CLIMP-63-binding proteins. Two separate
experiments identiﬁed 14-3-3y (experiment no. 1: six unique peptides, experiment
no. 2: four unique peptides), 14-3-3b (experiment no. 1: four unique peptides,
experiment no. 2: six unique peptides), 14-3-3z (experiment no. 1: two unique
peptides, experiment no. 2: four unique peptides), and 14-3-3e (experiment no. 1:
not identiﬁed, experiment no. 2: two unique peptides).
Western blotting. Proteins extracted from cells in lysis buffer were mixed with
SDS sample buffer with or without DTT (ﬁnal concentration of DTT at 0.6M),
resolved in a SDS-polyacrylamide gel, and transferred to PVDF membrane. After
blocking and primary antibody incubation, horseradish peroxidase (HRP)-
conjugated secondary antibodies with chemiluminescence (Pierce, Rockford, IL,
USA) were used to detect protein expression.
GTTR treatment and immunoﬂuorescence. GTTR was generated and
puriﬁed as described previously.
10 All the following steps of incubation before ﬁxation
were performed under normal culture condition (371C, 5% CO2). Cells were
preincubated in culture medium containing 2mg/ml HRP (Sigma) for 30min, and then
washed twice and incubated in normal medium for 30min before GTTR treatment.
Cellswereincubatedwith5mg/mlGTTRinmediumfor1handwashedwithPBSthree
times before ﬁxation with 4% of formaldehyde. To quench lysosomal ﬂuorescence,
ﬁxed cells were incubated in diaminobenzidine solution (Vector Laboratories,
Burlingame, CA, USA) for 5min, before permeabilization with 0.2% Triton X-100 for
immunoﬂuorescence. After blocking and primary antibody incubation, samples were
incubated with AlexaFluor 488-conjugated secondary antibody (Invitrogen, Carlsbad,
CA, USA) and protein expression was detected by confocal microscopy.
RT-PCR. Total RNA was extracted from mouse tissues or cells using RNeasy
Mini Kit (Qiagen, Valencia, CA, USA), and cDNA was synthesized using
SuperScript III First-Strand Synthesis System (Invitrogen). For mouse tissue
comparison, cDNA was synthesized from FirstChoice Mouse Total RNA (Ambion,
Austin,TX,USA). PCRwas performedusingthecDNA astemplate, AmpliTaqDNA
polymerase (Applied Biosystems), and primers speciﬁc for mouse CLIMP-63 (50-
CAGCGACTTGAAGGAGCTGAAG-30 and 50-ACAACCTATCCAGGTCGTTCC
G-30), b-actin (50-TGTTGCTCTAGACTTCGAGCAG-30 and 50-ACCGATCCAC
ACAGAGTACTTG-30) or GAPDH (50-ATGTGTCCGTCGTGGATCTGAC-30 and
50TACTCCTTGGAGGCCATGTAGG-30).
GSTfusionproteingenerationandpull-downassays. Thecytosolic
and lumenal domains of human CLIMP-63 cDNA (IMAGE clone 6084968, ATCC,
Manassas, VA, USA) were subcloned into pGEX5X-1 vector, by PCR ampliﬁcation
of each domain with following primers: for the cytosolic domain, 50-CC
CGAATTCATGCCCTCGGCCAAACAAAGG-30 and 50-AAACTCGAGCCTGCCGA
GCCTGCGCGAGCAG-30, and for the lumenal domain, 50-CCCGAATTCCAC
CACGTCCTGGAGGAGGTC-30 and 50-GGGCTCGAGTTAGACCTTTTCGTGAAT
CTTCTC-30. The resultant constructs were transformed into BL21 for bacterial
protein expression. The GST fusions were generated and puriﬁed using BugBuster
GSTKBind Puriﬁcation Kit (Novagen, Gibbstown, NJ, USA). Gentamicin–agarose
pull-down assay was performed using lysis buffer containing 150mM NaCl, 20mM
Tris (pH 7.5), 0.2% Triton X-100, 10% glycerol. For GST fusion protein pull-down
assay, 5mg GST or GST fusion protein was bound to 30ml of 50% slurry of
GSTKBind resin at 41C for 2h in GSTKBind Wash buffer. After washing for three
times, cell lysate was mixed with the resin, and binding was performed at 41C for
2h. Washing was performed with the lysis buffer four times after binding, and the
proteins were removed from the resin in SDS sample buffer.
FLAG immunoprecipitation. Anti-FLAG M2 afﬁnity gel (30ml; Sigma) was
mixed with lysate from cells transfected with FLAG-tagged protein, and binding was
performed at 41C for 2h. After washing with Tris-buffered Saline for three times,
bound proteins were eluted with 3  FLAG peptide (Sigma) at 41C for 30min. For
silver staining, SilverQuest Silver Staining Kit (Invitrogen) was used according to
manufacturer’s instruction.
Transfection. Two sets of siRNA for CLIMP-63 and scrambled control
were designed and synthesized using Invitrogen’s service. The sequences for
CLIMP-63 siRNA are: no. 1 50-CCAAGUCUAUCAAUGACAATT-30 and no. 2
50-GCAGAAUGAGAUUCUCAAATT-30. For 14-3-3 siRNA, the sequences are:
14-3-3b 50-UUUGUCCAACAGCUCCAGCTT-30 and 14-3-3y 50-GCAGCUGAUCA
AGGACUAUTT-30. Control siRNA are scrambled sequences of the respective
siRNA. Transfection of siRNA was performed using Lipofectamine RNAiMAX
(Invitrogen). For expression plasmid transfection into 293T or COS-7 cells, human
CLIMP-63 was subcloned into pcDNA3.1 vector. The point mutations were
introducedbyQuikChangeSite-DirectedMutagenesisKit(Stratagene,LaJolla,CA,
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CGCGAGGAGGACGCCGAG-30 for C100S mutant, and 50-CCTCGGCGTCC
GCCTCGCGCAGGC-30 and 50-GCCTGCGCGAGGCGGACGCCGAGG-30 for
C100A mutant. The resultant plasmids were sequenced to conﬁrm that there is
no false mutation within the coding region of CLIMP-63. For 14-3-3 protein
expression, human 14-3-3b and y cDNA clones (cat. no. SC118005 and
SC115879) were obtained from OriGene (Rockville, MD, USA), and subcloned into
pFLAG-CMV2 vector, or pcDNA3.1 with addition of a Myc tag at the N-terminus.
Plasmid transfection was carried out using LipofectAMINE 2000 (Invitrogen).
Cell viabilitymeasurements. Cell viability was determinedby the reduction
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), an indicator
ofmitochondrialdehydrogenaseactivity.Cellswereplatedat10000cellsperwellin
a 96-well plate. After incubation overnight to allow cells to attach to the plate, cells
were treated with gentamicin in culture medium for 3 days. For siRNA-transfected
cells, cells were incubated for 3 days to ensure maximum knock down before 3-day
gentamicin treatment. Cells were initially plated at 2500 cells per well to allow 6-day
culturing (3-day transfection plus 3-day gentamicin treatment) without cellular
overgrowth. There was no signiﬁcant cellular detachment from plates by cell death
duringthe 3-day transfection. After 3 daysof gentamicintreatment,20ml of 5mg/ml
of MTT solution was added to each well, and cells were incubated for 4h at 371C,
5%CO2.Culturemediumwasthenreplacedwith200mlDMSOineachwell,andthe
optical density recorded at 540nm with background subtraction at 660nm.
Caspase-3 assay. Cells were plated at 2 10
5 cells per 60-mm dish. For
KPT11 cells to be transfected with siRNA, cells were plated at 1.5 10
5 cells per dish.
After incubation overnight, cells were treated with gentamicin in culture medium for 12,
24, or 48h. Caspase-3 activity was determined by using CaspACE Assay System
(Promega, Madison, WI, USA), according to the manufacturer’s instructions.
TUNEL assay. After 3 days of siRNA transfection followed by 24-h gentamicin
treatment, DNA strand breaks were labeled by TUNEL reaction by using In Situ
Cell Detection Kit (Roche Applied Science, Indianapolis, IN, USA), and detected by
confocal microscopy. Double-labeling with AlexaFluor 568-conjugated phalloidin
was performed to visualize the ﬁlamentous actin cytoskeleton.
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